The global cytokine release syndrome management market is on track for substantial growth, with an estimated value of USD 23.32 billion in 2023. The market is projected to expand at a compound annual growth rate (CAGR) of 6.7% from 2023 to 2033, reaching an anticipated USD 44.6 billion by 2033. This growth is primarily driven by the increasing prevalence of autoimmune diseases and cancers, both of which contribute to the rising incidence of CRS.
Cytokine Release Syndrome, a life-threatening condition often triggered by immunotherapies, requires prompt intervention. The treatment landscape has been revolutionized by new-generation drugs like tocilizumab, siltuximab, and anakinra, which target pro-inflammatory cytokines to reduce the severity of CRS. These therapies, coupled with aggressive supportive care, including fluid resuscitation, anti-emesis, and anti-diarrhea medications, are improving outcomes for patients and significantly mitigating CRS symptoms.
The future of CRS management looks promising, with ongoing studies aimed at uncovering the underlying mechanisms of CRS and exploring additional treatment options. Researchers and healthcare providers are optimistic that these studies will lead to even more effective interventions in the near future, further enhancing patient care and outcomes.
As the global CRS management market grows, it is expected to see an influx of innovative treatments and therapies, marking a transformative shift in the way the condition is approached and treated.
Key Takeaways from the Market Study:
- Globally, the cytokine release syndrome management market is expected to reach USD 23.32 billion by 2023.
- This market is estimated to reach USD 44.6 billion by 2033.
- Hospitals for cytokine release syndrome management are expected to grow 32% market share between 2023 and 2033.
- The market for Tumour Necrosis Factor-TNF is projected to grow by 2.9% from 2023 to 2033.
- Cytokine release syndrome management in North America expanded with a market share of 17% during the forecast period.
- According to forecasts, the arthritis therapeutics market accumulate a share of 19% over the next few years.
“Advances in immunotherapies, the approval of new drugs, and CAR T-cell therapies are expected to further accelerate the growth of the cytokine release syndrome management market.” comments a Future Market Insights analyst.
Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!
Competitive Landscape:
The development of innovative diagnostic techniques is becoming increasingly important for companies, which will probably lead to a number of firms expanding their product lines, acquiring other companies, or merging their companies in the near future, as many are likely to focus on developing new diagnostic techniques.
- Kite announced that the Food and Drug Administration (FDA) has approved the addition of prophylactic corticosteroids to the prescribing information for Yescarta®. The label on Yescarta includes information to guide physicians in managing and possibly preventing side effects associated with chimeric antigen receptor (CAR) T-cell therapies. To maximize the chances of CAR T-cell therapy being beneficial to as many patients as possible, Kite has been working closely with physicians since Yescarta’s first approval in 2012. CAR T therapy research is also focused on expanding into new diseases and early treatment lines, while continuously enhancing the safety and efficacy of existing treatments.
- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., reported stable response rates among 6 patients with relapsed/refractory AL amyloidosis using NXC-201. Six relapsed/refractory AL amyloidosis patients treated with NXC-201 have shown 100% complete response. Using clinical cancer research, 100% complete responses were observed; 100% organ responses were observed; and at 5.2 months, the duration of response was still unknown, resulting in an average reduction of 65% (2,656 pg/mL) in NT-proBNP from baseline. There was no grade 4 Cytokine Release Syndrome. ICANS neurotoxicity was not observed; NYHA stage improved by 2 stages.
Key Companies Profiled:
Hoffmann-La Roche Ltd; GlaxoSmithKline Plc; Novartis AG; Sanofi S.A; Pfizer Inc.; Bayer AG; Biocon; AbbVie Inc.; Johnson & Johnson Private Limited; Incyte Corporation; Swedish Orphan Biovitrum; Genentech
Key Segments Profiled in the Cytokine Release Syndrome Management Industry Survey:
By Cytokine Type:
- Tumor Necrosis Factor-TNF
- Interleukins-II
- Interferons-IFN
- Epidermal Growth Factor-EGF
By Therapeutic Application:
- Cancer
- Asthma
- Airway Inflammation
- Arthritis
- Others
By Biomarker Type:
- Interleukin-10
- Interferon Gamma
- Interleukin-6
- Ferritin
- Cluster of Differentiation-163
By Route of Administration:
- Oral
- Intravenous
By End User:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:
Europe Viscosupplementation Industry
Arthroscopy Procedure and Products Industry
Electronic Medical Records (EMR) Industry
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube